YieldMax MRNA Option Income Strategy ETF is rated a Sell due to heightened downside risk and overvalued pipeline optimism.

The researchers identified a driving force behind the condition, opening up a potential target for new therapies.

Penn Medicine scientists blend AI and ingenuity to transform mRNA gene editing and personalized therapies redefining modern ...

SkinJect™ , a novel localized immuno-oncology precision product focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) and Gorlin Syndrome , a rare autosomal dominant disease ...

Pfizer Inc. (NYSE:PFE) plays a significant role in global healthcare by supplying medicines and vaccines to healthcare ...

Learn what the Nipah virus is, how it spreads, and why it has one of the highest fatality rates among infectious diseases.

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs ...

After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its ...

The May meeting thus serves as a ratification of BioNTech's new architecture for the post-pandemic era. The votes will legitimize the structural and financial framework designed to bridge the company ...

Sunshine Biopharma is embarking on a stringent cost-cutting initiative as it navigates a mixed financial outcome for the 2025 fiscal year. The company's strategy aims to shore up its financial ...

A specific protein controls mRNA transport in fungi and distinguishes important from unimportant binding sites in the ...

Northwestern Medicine scientists have discovered that a specific long non-coding RNA activates oncogenic signaling pathways ...